$20.960
-0.574 (-2.74%)收盘时
HQL 盈利能力与利润率
Evaluating the bottom line, Abrdn Life Sciences Investors maintains a gross margin of 99.06%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 94.87%, while the net margin is 94.87%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively HQL converts its operational activities into shareholder value.
Financials
No data
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。